Clinical Trials Logo

Amphetamine-related Disorders clinical trials

View clinical trials related to Amphetamine-related Disorders.

Filter by:

NCT ID: NCT04687566 Recruiting - Clinical trials for Amphetamine Addiction

Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction

Start date: August 11, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators will conducted a randomized double-blind placebo-controlled study to investigate the treatment outcomes of add-on low dose dextromethorphan (DM), memantine (MM), or dextromethorphan and memantine combination (DM+MM) in amphetamine-type stimulants use disorder patients.

NCT ID: NCT04531384 Not yet recruiting - Clinical trials for Amphetamine Addiction

Robot-Assisted Intelligent Rehabilitation Treatment for Methamphetamine Use Disorders.

Start date: December 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to evaluate the efficacy and safety of Robot-assisted rehabilitation intelligent system as a virtual stand-alone treatment, delivered with minimal clinical monitoring compared with treatment as usual in methamphetamine (MA) use disorders.

NCT ID: NCT04203654 Recruiting - Clinical trials for Amphetamine-Related Disorders

Implementation and Effectiveness of Multidiscipline-Integrated Addiction Treatment Model

Start date: February 24, 2020
Phase: N/A
Study type: Interventional

Management of substance use disorders in clinical settings is challenging. Approaches with integrated bio-psycho-social interventions, along with the engagement of families and self-help groups are strongly recommended. The Matrix intensive outpatient program has been developed in UCLA to help the psychostimulant misusers in the Southern California in 1980's. With integration of the existing evidence of addiction researches and empirically supported cognitive-behavior treatment techniques, the Matrix model developed manuals to address knowledge and skills needed for drug users in their early recovery and relapse prevention. The treatment was delivered in a 16-week intensive structured group sessions. There was also a 12-week educational sessions for the in-treatment individuals and their families. A substantial body of evidence has demonstrated the successful experience of the Matrix treatment model in management a broad spectrum of addictive disorders in many countries. The objectives of the pilot project are to set up a multi-center collaborative clinical network with implementation of an integrated addiction treatment program modified from the UCLA Matrix model. Via the establishment of standardized subject recruitment criteria, treatment and outcome assessment procedures, the study aims to assess the adherence of participating clinical organizations to the study protocol, the acceptance of participating MA misusers for the integrated treatment program as well as the outcomes and their determinants for the treatment models.

NCT ID: NCT03902405 Recruiting - Clinical trials for Substance-Related Disorders

Computerized Exercise to Alter Stimulant Approach Responses

CEASAR
Start date: June 11, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the Computerized Exercise to Alter Stimulant Approach Responses (CEASAR), a novel stimulant use cessation intervention, for clients currently enrolled in a treatment centre for mental health and addiction. The investigators plan to conduct a randomized, single-blind controlled trial involving inpatients presenting with concurrent disorders to test the impact of this novel computerized intervention. This pilot study will be conducted at the Burnaby Centre for Mental Health and Addiction (BCMHA) in Burnaby, BC, Canada.

NCT ID: NCT03318081 Completed - Clinical trials for Amphetamine Addiction

The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction

Start date: October 20, 2017
Phase: N/A
Study type: Interventional

The computerized cognitive rehabilitation therapy will be used to treat amphetamine-type stimulant (ATS) addiction.

NCT ID: NCT03221283 Completed - Clinical trials for Amphetamine Addiction

The Application of Music Therapy in Female Amphetamine Use Disorder

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

The group music therapy will be used to treat female amphetamine-type stimulant (ATS) addiction

NCT ID: NCT02952196 Withdrawn - Clinical trials for Amphetamine Addiction

Cannabioids as a New Intervention for Amphetamine Dependence

Start date: November 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02950376 Completed - Clinical trials for Amphetamine Addiction

The Novel Addiction Assessment Study in Synthetic Drugs Addiction

Start date: December 2016
Phase:
Study type: Observational

The purpose of this research is to develop an objective assessment based on the virtual reality techniques which is used for evaluate addiction severity.

NCT ID: NCT02836756 Not yet recruiting - Clinical trials for Amphetamine Addiction

Cannabidiol as a New Intervention for Amphetamine Dependence

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder. Our overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02797990 Completed - Pregnancy Clinical Trials

Conflict Between Maternal Autonomy and Child Health in Substance-use

Start date: May 2016
Phase: N/A
Study type: Observational

Qualitative project, comprising open-ended semi-structured interviews with healthcare workers, who provide antenatal care to substance-using women.